Clinuvel Pharmaceuticals (CUV) H2 2025 earnings summary

Executive summary

• Achieved ninth consecutive annual profit and eighth consecutive annual dividend, with the fourth fully franked.

• Revenue grew 10% year-over-year to $105 million, surpassing the $100 million mark.

• Strong, consistent financial performance in FY2025 with global growth and controlled expenses.

• Continued reinvestment in R&D to support future revenue streams and brand visibility.

• Expansion of trained and accredited sites in North America to 104, targeting 120 by year-end.

Financial highlights

• Net profit after income tax was $36.2 million, a 20% increase year-over-year.

• Net profit margin reached 34%, about 8% above industry average for similar-stage biotechs.

• Cash reserves stood at $224.1 million, up 22% from the previous year, boosting free cash flow.

• No capital raised or dilutionary events since 2016; company remains debt-free for 20 years.

• Dividend per share declared at $0.05, stable year-over-year.

Outlook and guidance

• Three-year budget to be released in H2 2025, with internal targets of $50–$55 million annual expenditures.

• Cash reserves provide operational coverage for 3–4 years, supporting R&D and potential acquisitions.

• Key upcoming milestones: Health Canada and EMA decisions on SCENESSE®, vitiligo trial updates, and first CUV105 readout in H2 2026.

• Plans to upgrade ADR level and list 8% of U.S. shareholdings on NASDAQ.